RT Journal Article
SR Electronic
T1 Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.06.20249035
DO 10.1101/2021.01.06.20249035
A1 Steenhuis, Maurice
A1 van Mierlo, Gerard
A1 Derksen, Ninotska I.L.
A1 Ooijevaar-de Heer, Pleuni
A1 Kruithof, Simone
A1 Loeff, Floris L.
A1 Berkhout, Lea C.
A1 Linty, Federica
A1 Reusken, Chantal
A1 Reimerink, Johan
A1 Hogema, Boris
A1 Zaaijer, Hans
A1 van de Watering, Leo
A1 Swaneveld, Francis
A1 van Gils, Marit J.
A1 Bosch, Berend Jan
A1 van Ham, Marieke
A1 Brinke, Anja ten
A1 Vidarsson, Gestur
A1 van der Schoot, Ellen C.
A1 Rispens, Theo
YR 2021
UL http://medrxiv.org/content/early/2021/01/06/2021.01.06.20249035.abstract
AB The novel SARS-CoV-2 virus emerged in late 2019 and has caused a global health and economic crisis. The characterization of the human antibody response to SARS-CoV-2 infection is vital for serosurveillance purposes as well for treatment options such as transfusion with convalescent plasma or immunoglobin products derived from convalescent plasma. In this study, we measured antibody responses in 844 longitudinal samples from 151 RT-PCR positive SARS-CoV-2 convalescent adults during the first 34 weeks after onset of symptoms. All donors were seropositive at the first sampling moment and only one donor seroreverted during follow-up analysis. Anti-RBD IgG and anti-nucleocapsid IgG levels slowly declined with median half-life’s of 62 and 59 days during 2-5 months after symptom onset, respectively. The rate of decline of antibody levels diminished during extended follow-up. In addition, the magnitude of the IgG response correlated with neutralization capacity measured in a classic plaque reduction assay as well in our in-house developed competition assay. The result of this study gives valuable insight into the longitudinal response of antibodies to SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the European Commission (SUPPORT-E, grant number 101015756) and by ZonMW (Protective Immunity, grant number 10430 01 201 0012).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data and samples were collected only from voluntary, non-remunerated, adult donors who provided written informed consent as part of routine donor selection and blood collection procedures, that were approved by the Ethics Advisory Council of Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon reasonable request (by contacting the corresponding author).RBDreceptor binding domainNPnucleocapsid proteinSspikeSARS-CoV-2severe acute respiratory syndrome coronavirus 2ACE2angiotension converting enzyme-2VNT50virus neutralization titer 50%AbantibodyPTGPBS supplemented with 0.02% polysorbate-20 and 0.3% gelatin